Biomarkers Related to PSCI: An fNIRS Study
Launched by DINGQUN BAI · Nov 21, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Biomarkers Related to PSCI: An fNIRS Study," is focused on understanding how stroke affects thinking and memory, which is known as cognitive impairment. The researchers are using a special technique called fNIRS to find markers in the brain that could help identify changes in cognition after a stroke. This study is currently looking for participants, including both stroke patients and healthy individuals aged 18 to 80.
To be eligible, stroke patients need to have a confirmed stroke diagnosis through imaging tests like CT scans or MRIs and must be able to complete cognitive tasks. Healthy participants should not have any brain abnormalities and must also be able to complete these tasks. During the trial, participants will undergo tests to assess their brain function and cognitive abilities. It's important to note that individuals with serious health issues, mental illnesses, or certain medical conditions, such as metal implants, cannot participate. Overall, this study aims to improve our understanding of how stroke impacts thinking, which could lead to better care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Stroke patients:
- • 1. Diagnosis of stroke confirmed by neuroimaging (CT or MRI)
- • 2. 18-80 years old
- • 3. Able to complete the cognitive task
- • 4. Able to follow instructions to complete the trial
- • 5. Patients who signed an informed consent form.
- Healthy Subjects:
- • 1. No abnormalities on cranial
- • 2. 18-80 years old
- • 3. Able to complete cognitive task
- • 4. Able to follow instructions to complete the trial
- • 5. not taking medications.
- • 6. Subjects who signed an informed consent form.
- Exclusion Criteria:
- Stroke patients:
- • 1. Inability to tolerate the test due to organic diseases
- • 2. Serious mental illness that prevents them from cooperating with or tolerating the trial
- • 3. Pregnant or lactating women
- • 4. Had metal implants, a history of other neurological disorders, acute cardiopulmonary dysfunction.
- Healthy Subjects:
- • 1. Inability to tolerate the test due to organic diseases
- • 2. Serious mental illness that prevents them from cooperating with or tolerating the trial.
- • 3. Pregnant or lactating women
- • 4. Had metal implants, a history of other neurological disorders, acute cardiopulmonary dysfunction
About Dingqun Bai
Dingqun Bai is a dedicated clinical trial sponsor focused on advancing innovative therapeutic solutions through rigorous research and development. With a commitment to enhancing patient outcomes, the organization collaborates with leading healthcare professionals and institutions to design and execute high-quality clinical trials. Dingqun Bai emphasizes scientific integrity and regulatory compliance, ensuring that all studies are conducted with the utmost attention to ethical standards and patient safety. Through its strategic approach and expertise, the sponsor aims to contribute significantly to the evolving landscape of medical treatments and improve healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, Chongqing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported